Left Menu
Development News Edition

NHS England, Biogen reach deal on pricey drug for deadly disorder

Devdiscourse News Desk | London | Updated: 15-05-2019 05:32 IST | Created: 15-05-2019 04:31 IST
NHS England, Biogen reach deal on pricey drug for deadly disorder
Image Credit: (Pixabay)
England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza. NHS England said it reached a "managed access agreement" with Biogen under which it will fund treatment for a limited time and collect data on the drug's effectiveness.

NHS England did not disclose the price it will pay for the drug. Biogen confirmed the deal on Tuesday and said it applauded the decision by the National Institute for Health and Care Excellence to recommend funding for Spinraza in the United Kingdom.

Spinraza, which is administered by spinal injection every four months, has a U.S. list price of $750,000 for the first year and $375,000 annually thereafter. Britain's healthcare cost agency, NICE, said in August it could not recommend Spinraza as a cost effective treatment. The rejection came despite a lower British price tag of 450,000 pounds ($573,000) for the first year and Biogen offering an undisclosed discount to the National Health Service.

Spinal muscular atrophy (SMA) is the leading genetic cause of infant mortality, affecting one in every 10,000 live births. About 60 percent of patients have the most severe Type 1 form of the disease, which often leads to paralysis, impaired breathing and death by the second birthday. Between 600 and 1,200 children and adults are currently living with the condition in England and Wales, according to NHS England. Spinraza will be made available immediately to Type 1 patients by Biogen, it said.

It said that Spinraza will be made available for other patients - including adults and siblings who have yet to show symptoms - in a few weeks, after NICE publishes guidance. Spinraza was the first approved treatment for SMA, but is expected to soon face new competition. The U.S. Food and Drug Administration is due to decide on approval for Novartis' gene therapy Zolgensma this month, with other regulators expected to follow suit later this year.

Novartis says the one-time treatment could be a cure for SMA and is pushing for a price in the range of $1.5 million to $5 million. That would make Zolgensma the most expensive new therapy. (Reporting by Michael Erman; Additional reporting by Caroline Humer and Rishika Chatterjee; editing by Bill Berkrot)


TRENDING

OPINION / BLOG / INTERVIEW

Rethinking Rural Livelihoods in the Times of COVID-19

The reverse migration caused by COVID 19 pandemic has put an additional burden of about one crore people on Indian villages particularly in the states of Uttar Pradesh, Bihar, Bengal and Odisha. Besides increasing the risk of spreading the ...

‘Discounted Deaths’ and COVID 19: Anthropology of Death and Emotions

Death is a social event rather than the mere cessation of biological functions. As seen by anthropologists, death is not just physical but intensely social, cultural, and political....

Indigenous knowledge of communities a must for maximizing impact of community work

Generally, it has been observed that the majority of the academicians in higher education institutions neglect the wisdom of community people and throw their weight around thinking that they know everything and the community knows nothing. ...

In rebuking FBR, Pakistan’s courts take a stand for public health

The system, if implemented effectively, will allow Pakistans revenue service to combat the illicit trade in tobacco products and potentially add hundreds of millions of dollars to the states budget each year. ...

Videos

Latest News

Study authors retract influential Lancet hydroxychloroquine article

Three of the authors of an influential article that found hydroxychloroquine increased the risk of death in COVID-19 patients retracted the study on Thursday, citing concerns about the quality of the data behind it. The anti-malarial drug h...

'This is not New York': Mexico president defends coronavirus response

Mexican President Andres Manuel Lopez Obrador on Thursday defended his governments handling of the coronavirus outbreak after a broader method of counting deaths led to an all-time daily high, outstripping even the United States.The health ...

US STOCKS-S&P 500 closes down, snapping four-day rally

The SP 500 lost ground on Thursday as investors took profits in advance of Fridays jobs report, ending a four-day rally driven by rising economic sentiment. The Nasdaq joined the SP 500 in negative territory, while the blue-chip Dow posted ...

EXCLUSIVE-Pompeo to urge stock exchanges globally to tighten rules for Chinese companies

U.S. Secretary of State Mike Pompeo plans to warn American investors against fraudulent accounting practices of China-based companies and suggest the Nasdaqs recent decision to tighten listing rules for such players should be a model for al...

Give Feedback